Repare Therapeutics (NASDAQ:RPTX) Upgraded to Hold at Wall Street Zen

Key Points

• Repare Therapeutics has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a more favorable outlook for the company.
• The company reported a quarterly earnings per share of ($0.39), exceeding analysts' expectations by $0.17.
• Institutional investors hold a significant stake in Repare Therapeutics, with 85.09% of the stock owned by hedge funds and institutional investors.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Repare Therapeutics Stock Up 0.6%

RPTX traded up $0.01 during midday trading on Friday, reaching $1.57. 33,941 shares of the company's stock were exchanged, compared to its average volume of 315,487. The firm has a market capitalization of $67.45 million, a price-to-earnings ratio of -0.61 and a beta of 0.93. Repare Therapeutics has a one year low of $0.89 and a one year high of $4.07. The business has a 50-day simple moving average of $1.48 and a two-hundred day simple moving average of $1.30.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.17. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, research analysts anticipate that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Institutional Trading of Repare Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in shares of Repare Therapeutics by 65.5% in the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company's stock valued at $224,000 after purchasing an additional 67,638 shares in the last quarter. Stifel Financial Corp increased its holdings in shares of Repare Therapeutics by 73.1% in the fourth quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock valued at $117,000 after purchasing an additional 37,800 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Repare Therapeutics by 204.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock valued at $45,000 after purchasing an additional 23,127 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Repare Therapeutics in the fourth quarter valued at approximately $104,000. Finally, JPMorgan Chase & Co. grew its holdings in Repare Therapeutics by 2,144,950.0% during the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after acquiring an additional 85,798 shares during the period. Institutional investors and hedge funds own 85.09% of the company's stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.